AstraZeneca confirmed Monday morning that it is “exploring potential strategic options” with Acerta Pharma BV.
Acerta is a privately held biopharmaceutical company with offices in California and The Netherlands. Its lead product is an experimental blood cancer drug, called acalabrutinib, which is in late-stage clinical testing.
{iframe}http://www.bizjournals.com/philadelphia/news/2015/12/14/astrazeneca-confirms-interest-in-a-5b-purchase.html?ana=e_phil_bn_breakingnews&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1450115227{/iframe}